Beyond AChR: Recognizing and Treating MuSK Ab+, LRP4 Ab+ and Triple Seronegative Myasthenia Gravis

https://checkrare.com/learning/p-beyond-achr-recognizing-and-treating-musk-ab-lrp4-ab-and-triple-seronegative-myasthenia-gravis/ This accredited CME program examines best practices to diagnose and treat patients with ultra-rare forms of myasthenia gravis. The most prevalent form of myasthenia gravis is associated with antibodies against the acetylcholine receptor (AChR Ab+). However, 15- 20% of patients with myasthenia gravis are not AChR Ab+. These clinically important and underrecognized subsets of patients harbor antibodies against muscle-specific kinase (MuSK Ab+) lipoprotein receptor-related protein 4 (LRP4 Ab+), or test negative for all known antibodies (triple seronegative MG). These patients present unique diagnostic and treatment challenges that necessitate expert guidance to improve their management.